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Abstract Glioblastomas are highly malignant primary
brain tumors with one of the worst survival rates among
all human cancers. With a more profound understanding of
the cellular and molecular mechanisms of tumor initiation
and acquired resistance to conventional radio- and chemo-
therapy, novel therapeutic targets might be discovered to
optimize therapeutic approaches. In this regard, the identi-
fication of a small cellular subpopulation, called glioblas-
toma stem cell or stem-like cells or glioma-initiating cells
or brain tumor propagating cells, has gained attention. In
this article, we briefly summarize the current state of
knowledge about this tumor cell population and discuss
future directions for basic and clinical research.
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Stem cell and cancer biology
A histological key feature of glioblastomas is the cellular
and morphological heterogeneity and the parallel detection
of cell populations of apparently different grades of
differentiation. Moreover, glioblastomas harbor a variety
of genetic abnormalities. This tumor heterogeneity may
pose a therapeutic challenge because different cell popula-
tions within the tumor tissue might respond differently to
therapies. One strategy to overcome these problems is to
identify and characterize distinct subpopulations that drive
specific disease pathologies, e.g. tumor initiation or tumor
recurrence or both.
In this regard, overlaps have been defined in stem cell
biology and oncology, particularly because of the growing
evidence demonstrating that genes with important roles in
stem cell biology also play a role for cancer biology.
Consequently, the existence of a stem-like tumor cell was
hypothesized, i.e. a relatively small percentage of cells that
drive tumorigenesis and maintain tumor viability despite
multimodal anticancer therapy. Candidate cancer stem cells
should display several features that signify stemness
including the unique ability to morphologically recapitulate
the tumor of origin in xenografts.
The first experimental evidence for the actual existence
of cancer stem cells came from hematological malignan-
cies. Studies of acute myeloid leukemia (AML) revealed
that a single cell initiated the disease after transplantation in
mice. Cell isolation depending on cell surface marker
expression revealed that CD34+CD38+ cells initiated
AML, whereas CD34+CD38− did not. After development
of AML in mice, the frequency of these leukemia-initiating
cells in peripheral blood was about 1,000-fold lower than
the frequency of other leukemic cells. These findings
suggested that a hierarchy of leukemic stem cells existed
in human AML (Lapidot et al. 1994).
This hierarchical model implies that the majority of
cancer cells within a tumor are derived from a few cancer
stem cells. Thus, the tumor consists in a small subset of
cancer stem cells and a large population of bulk cells that
cannot per se form new tumors and might represent a mix
of partially and terminally differentiated cancer cells with
limited proliferative capacity.
This concept was also investigated in brain tumors. The
seminal study in the field of neurooncology demonstrated
that as few as 100 glioma stem-like cells, defined as
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CD133+ cells, were able to recapitulate the heterogeneity of
glioblastomas in immunocompromised mice whereas
CD133− tumor cells could not. Notably, 100 CD133+ cells
sufficed to recapitulate the original tumor whereas 10,000
CD133− cells were not tumorigenic (Singh et al. 2004).
Therefore, a hierarchy was postulated in gliomas, i.e. a
tumor cell of origin that upon differentiation might lead to
the establishment of astrocytomas, oligodendrogliomas or
ependymomas (Fig. 1).
Several other groups have also isolated brain tumor stem
cells from primary glioblastomas, based on cell surface
marker expression or the ability to form neurospheres (also
called gliomaspheres) as do normal neural stem cells
(Table 1).
The identification of somatic mutations of the isocitrate
dehydrogenase 1 gene (IDH1) most frequently found in
glioblastomas which has evolved from lower-grade glio-
mas, so-called secondary glioblastomas, might be of
relevance for further characterization of a putative cell of
origin in gliomas, i.e. a cell of origin in gliomas that upon
differentiation might lead to the establishment of astrocy-
tomas or oligodendrogliomas (Fig. 1). Low-grade gliomas
(astrocytomas and oligodendrogliomas) may carry IDH
mutations in the absence of any other genetic aberration,
suggesting that IDH mutations occur early, e.g. in a stem or
precursor cell that can give rise to both, astrocytes and
oligodendrocytes (Yan et al. 2009). Interestingly, IDH
mutations never occur in ependymomas.
The nomenclature
The nomenclature of stem cells in glioblastoma has
remained controversial. This is due to the lack of
standardized criteria for identifying them. The terms
glioblastoma stem cell, glioblastoma stem-like cell or
glioblastoma-initiating cell are commonly used inter-
changeably but whether cells identified by the methods
defined below are the only cells that can initiate tumors has
remained unclear. This terminology reflects some shared
characteristics with normal stem cells, especially adult
somatic stem cells, including the capacities for self-
renewal, differentiation and maintained proliferation. Yet,
whether the cell of origin in glioblastomas is sometimes or
always a stem cell (Fig. 1), as the terminology glioblastoma
stem cell implies, is unclear at the moment. The term tumor-
propagating cell has been alternatively proposed, because the
defining bioassay involves tumor propagation in secondary
hosts, e.g. mice (Kelly et al. 2007). In this article, we use the
term glioblastoma stem-like cell (GSC) and are fully aware
of controversies regarding its limitations.
Isolating and culturing GSC
GSC have been identified based on different cell surface
markers, culture conditions or functional criteria. Currently
used approaches are summarized in Table 1. The most
Fig. 1 Glioma stem-like cells might serve as a “cell of origin” either
derived from a transformed stem cell or a transformed somatic cell.
Further differentiation of this cell of origin might then lead to different
cellular lineages resulting in the development of astrocytomas,
oligodendrogliomas or ependymomas
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mentioned and controversial cell surface marker for GSC
isolation is CD133, a cholesterol-bindig membrane protein
of unknown biological function.
CD133+ progenitor cells promoted the healing of
ischemic ulcers through stimulating angiogenesis and
activating the Wnt pathway (Barcelos et al. 2009).
Recently, CD133 expression was demonstrated to increase
in response to hypoxia and to mitochondrial dysfunction.
This questions CD133 as a reliable marker for GSC.
One reason explaining these inconsistencies between
various groups could be the lack of standardization
regarding cell sorting methods and assays to confirm
“stemness” across laboratories.
Recently, a marker-independent approach has been
demonstrated exploiting cellular phenotypes. Combining
morphological aspects and autofluorescence emission were
used to enrich a subpopulation with self-renewal ability in
vitro, tumor-initiating and propagating capacity in vivo and
expression of stem cell-related genes (Clement et al. 2010).
Another ongoing debate exists on how to best culture
GSC to facilitate their study in vitro. The first studies
applied techniques used for culturing normal neural stem
cells. In neurobasal medium supplemented with growth
factors such as epidermal growth factor and basic fibroblast
growth factor, neural stem cells can be propagated and
expanded indefinitely, whereas most differentiating or
differentiated cells rapidly die (Reynolds and Weiss 1996).
This approach allowed the prospective GSC isolation from
fresh glioblastoma specimens, i.e. a subpopulation of cells
capable of proliferation, self-renewal and differentiation
(Singh et al. 2004). Some studies, on the other hand, have
proposed protocols for adherent cultures of GSC in serum-
free medium using attachment factors (Al-Mayhani et al.
2009; Pollard et al. 2009). The latter studies claim that
adherent monolayer cultures are superior to non-adherent
sphere cultures because of the possibility to ensure uniform
exposure to growth factors, oxygen and nutrients leading to
a more homogenous cell population.
The high relevance and the potential impact of in vitro
culturing conditions on cellular characteristics are underscored
by a study describing the emergence of cancer stem-like cells
from in vitro cultured adult rat subventricular zone stem cells.
After expansion in vitro, neural stem cells transformed into
tumorigenic cell lines that acquired multiple chromosomal
aberrations. They maintained characteristic stem cell expres-
sion markers like Nestin, Musashi-1 and CD133 but
continued to proliferate upon differentiation induction and
displayed tumorigenicity in vivo (Siebzehnrubl et al. 2009).
Functional evaluation of GSC in vitro and in vivo
The gold standard assay for investigating self-renewal and
tumor initiation of GSC is the ability to form tumors in
Table 1 Cell surface markers and functional assays for the isolation of glioma stem-like cells
Parameter Assessment Functional correlate Key reference
CD 133 Magnetic sorting or flow cytometry sorting
for CD133 expression
Self renewal Singh et al. 2004
Multipotency
Tumorigenicity in vivo
Alpha 6 integrin Sorting for alpha 6 integrin expression alone
or in combination with CD133 expression
by flow cytometry
High enrichment for cells with
self-renewal
Lathia et al. 2010
Sphere formation
Tumorigenicity in vivo
Culture condition Culture condition: serum-free medium
supplemented with EGF, FGF
Self renewal Galli et al. 2004
Multipotency Günther et al. 2008
Tumorigenicity in vivo
Side population Flow cytometry sorting based on exclusion of
Hoechst 33342 (side population)
Tumorigenicity in vivo only in
side population
Kondo et al. 2004
A2B5 Flow cytometry sorting for A2B5 and
CD133 expression
Tumorigenicity Ogden et al. 2008
ALDH1 activity Flow cytometry sorting for ALDH1 activity High ALDH1 levels keep glioma cells
in an undifferentiated state
Rasper et al. 2010
High ALDH1-expressing glioma cells
grow in neurospheres
ALDH1 inhibition induces differentiation
and reduces clonogenicity
Autofluorescence Intrinsic autofluorescence and morphology Self renewal Clement et al. 2010
Multipotency
Tumorigenicity in vivo
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animals after orthotopic transplantation even of very low
cell numbers. These tumors should resemble the morpho-
logical and immunohistochemical phenotype of the original
tumor. Further, serial dilutions should be performed, i.e. the
definition of the smallest cell number capable of generating
tumors in vivo. Finally, serial passaging, i.e. harvesting of
an in vivo established tumor and implantation into a
secondary mouse, should occur. Regarding these criteria,
GSC should display much greater tumorigenic potential
than corresponding non-stem tumor cells in vivo (Hemmati
et al. 2003; Galli et al. 2004; Singh et al. 2004).
Of note, the role of GSC beside tumor initiation has also
been studied in vivo: many key malignant features of
glioblastomas have been attributed to GSC, e.g. elevated
levels of vascular endothelial growth factor (VEGF) to
promote angiogenesis (Bao et al. 2006a, b), expression of
stromal-derived factor-1 (SDF-1) (Salmaggi et al. 2006),
and resistance to radiation therapy (Bao et al. 2006a, b).
In vitro, GSC can be induced to differentiate into
astrocytes, oligodendrocytes and neurons by addition of
serum and withdrawal of the culture conditions outlined
above (Hemmati et al. 2003; Galli et al. 2004; Singh et al.
2004). Given these standard functional assessments, it
remains to be clarified, however, how stable a GSC
phenotype is. This is of particular interest in the face of
studies suggesting the isolation of stem-like cells from
established glioma cell lines, e.g. GL-261 or C6 (Pellegatta
et al. 2006; Kondo et al. 2004).
Resistance of GSC to therapy
CD133 cell surface expression has been examined in
glioblastoma specimens from ten patients who had under-
gone surgical resection before and after high-dose irradia-
tion with gamma knife surgery and external beam radiation
therapy. Comparative analysis of histological sections
before and after radiation revealed that CD133+ cells were
very infrequent in primary tumor sections. In post-irradiated
tumors, however, the percentage of CD133+ cells was
significantly higher. The authors concluded that this
confirms the hypothesis that GSC are capable of escaping
high doses of radiation (Tamura et al. 2010). However,
studies showing that cellular stress induces CD133 must be
taken into account in interpreting these data. Probably,
CD133 increases after radiation therapy were due to CD133
induction on previously CD133− tumor cells, because—as
demonstrated by Griguer and colleagues—CD133 can be
induced by hypoxia and cellular stress (Griguer et al. 2008).
Preclinical evidence for resistance to therapy were
provided by Bao et al. (2006a, b). They performed colony
formations assays using untreated or irradiated CD133+ and
Table 2 Signaling pathways and molecules in glioma stem-like cells
Signaling molecule Biological role Evidence for therapeutic targeting Key reference
Chk1 and Chk2
kinases
DNA repair Inhibitors enhance radiosensitivity of GSC Bao et al. 2006a, b
EGFR Growth / proliferation signal EGFR kinase inhibitors inhibit proliferation
and self-renewal
Soeda et al. 2008
Akt Inhibitor blocks neurosphere formation,
induces apoptosis, reduces invasive
phenotype in vivo, impairs tumorigenicity
in vivo
Gallia et al. 2009
Notch Neural development Inhibition blocks self-renewal and promotes
radioresistance
Fan et al. 2010
TGF-beta Numerous cellular processes in normal
and neoplastic cells
Inhibition of TGF-beta interferes with
maintenance of GSC
Ikushima et al. 2009
Maintenance of GSC by induction of
leukemia inhibitory factor and the
Sox family members
BMP Neural development BMP 4 treatment induces differentiation Piccirillo et al. 2006
miR-124 ? Decreases proliferation and promotes
differentiation
Godlewski et al. 2010a
miR-137 ? Decreases proliferation and promotes
differentiation
Godlewski et al. 2010a
miR-128 ? Blocks self renewal and decreases
proliferation
Godlewski et al. 2010a
miR-7 Neural development muscle
differentiation
Inhibits migration and decreases
proliferation
Godlewski et al. 2010a
Chk Checkpoint kinase, EGFR epidermal growth factor receptor, TGF transforming growth factor, BMP bone morphogenetic protein
a For further details refer to this review article
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CD133− cells derived either from a biopsy specimen or
from glioma xenografts. These assays revealed a relative
radioresistance of CD133+ cells. Beier et al. (2008)
demonstrated on the other hand that temozolomide prefer-
entially depleted CD133+ cells in glioblastoma cancer stem
cell lines.
Therapeutic targets in GSC
Cell surface molecules differentially expressed in glioma
stem-like cells and functionally associated with the main-
tenance of glioma stem-like cells may be ideal targets for
therapeutic intervention. Several molecules including
CD133 and A2B5 (Singh et al. 2004; Son et al. 2009;
Tchoghandijan et al. 2010) have been discovered on the cell
surface of GSC (Table 1). A2B5 monoclonal antibodies
recognize GT3 gangliosides, which characterize a small
fraction of cells in the subcortical white matter with neural
stem cell properties. In glioblastomas, A2B5+ cells display
important features including migration and differentiation
into oligodendroglia and astroglial cells. Moreover, A2B5+
cells but not A2B5− cells form tumors in nude mice.
Interestingly, combining A2B5 and CD133 for cell isolation
revealed that both A2B5+/CD133+ and A2B5+/CD133−
cells formed tumors in nude mice (Tchoghandijan et al.
2010).
Further, identification of specific signaling pathways
involved in the maintenance and functions of GSC may
also identify useful therapeutic targets for novel strategies
to improve the treatment for glioblastoma. The signaling
pathways associated with GSC are summarized in Table 2.
Disruption of the Notch pathway by Notch shRNA
sensitized GSC to radiation therapy (Wang et al. 2009).
Differentiation therapy forcing GSC to differentiate might
be another promising and notably non-cytotoxic strategy
for GSC targeting. In this regard, bone morphogenetic
protein (BMP) 4 has been reported to activate BMP
receptors, triggering Smad signaling cascade in GSC and
leading to a reduction in GSC proliferation and increased
Fig. 2 Conventional radiotherapy might only hit glioma bulk cells
while glioma stem-like cells survive and are maintained by key
components of the tumor microenvironment. For succesful therapeutic
targeting, it will be important to design targeted therapies to interfere
with the signaling pathways maintaining glioma stem-like cells.
Combining radiotherapy with targeted anti-GSC therapy might then
diminish tumor recurrence
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expression of differentiated neural markers in CD133+ cells
(Piccirillo et al. 2006).
Novel important players include microRNAs, which have a
central role in gene expression. A role for microRNAs has
recently been established for cancers of different types,
including glioblastomas. A very comprehensive and detailed
overview on the role of miRNA in glioblastomas has recently
been published (Godleswski et al. 2010) (Table 2).
The preferential distribution of GSC in the perivas-
cular area has led to the identification of a GSC niche
(Calabrese et al. 2007). Disrupting the niche could
therefore be another therapeutic strategy. Thus, it is
important to identify specific elements in these regions
that maintain GSC. A role for endothelial cells as one
niche component seems to be established: Co-implantation
of GSC with endothelial cells accelerated tumor initiation
and progression (Calabrese et al. 2007). Apart from the
obvious interaction with endothelial cells, GSC are in
close contact with extracellular matrix components that are
preferentially expressed in the perivascular niche. Integrin
alpha 6 has been recently identified as an important
molecule for GSC in the perivascular niche (Lathia et al.
2010). It ensures interaction with laminin-expressing
endothelial cells in the microenvironment. Sorting by flow
cytometry based on alpha 6 expression alone or alpha 6
integrin/CD133 double-expression led to enrichment of
cells with a self renewal capacity in vitro and tumorige-
nicity in vivo. Targeted depletion of alpha 6 integrin by
lentiviral short hairpin RNA inhibited GSC growth and
sphere formation. Moreover, treatment with an alpha 6
integrin-blocking antibody reduced tumor formation in vivo.
Targeting integrin alpha 6 might be a promising strategy to
interfere with the niche and to impair self-renewal, prolifer-
ation and tumor initiation capacity (Lathia et al. 2010).
Further, it will be desirable to identify candidate
targets, e.g. for immunotherapy. It should be taken into
account, for example, that the human AC133 gene,
encoding CD133, has at least seven alternatively
spliced 5′-UTR isoforms of AC133 mRNA, which are
expressed in a tissue-dependent manner. The transcrip-
tion of these AC133 isoforms is driven by five different
promoters, P1–P5, depending on their location relative
to different exons. Finding the brain-specific isoform of
AC133 and targeting this specific isoform (Shmelkov et
al. 2004), e.g. by immunotherapy, will also increase the
specifity of these targeted approaches and decrease
potential toxicity.
Future perspectives
Selective GSC targeting will be challenging, even if highly
specific therapeutic targets are presently available, because
GSC may change and differently adapt in situ during the
course of the disease within a patient. Because of many
overlapping pathways and cell surface markers shared by
neural stem cells and GSC, however, one challenge will be
to identify therapeutic approaches that avoid potential
toxicities to normal neural stem cells.
Taken together, the identification of GSC has increased
the complexitiy of glioblastoma biology.
It remains to be determined to what extent the cells
defined by the current methodology give rise to gliomas
initially, maintain tumor viability during treatment and
promote clinical recurrence. Successful future therapeutic
approaches against glioblastoma will require a combination
of standard radiochemotherapy with tailored personalized
therapies targeting the unique molecular profile and GSC
profile of every patient (Fig. 2).
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